The Age-Related Macular Degeneration (AMD) Market size was valued at USD 10.52 Billion in 2023 and the total Age-Related Macular Degeneration (AMD) revenue is expected to grow at a CAGR of 6.9% from 2024 to 2030, reaching nearly USD 11.25 Billion by 2030. Macular Degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition characterized by blurred or absent vision in the center of the visual field. In its early stages, there may be no noticeable symptoms, but over time, some individuals experience a gradual deterioration of vision that can affect one or both eyes. While it does not lead to complete blindness, the loss of central vision can significantly impair daily activities such as recognizing faces, driving, reading, and other routine tasks. It's worth noting that visual hallucinations may occasionally occur, but these are not indicative of a mental illness. This condition primarily affects older individuals, with genetic predisposition and smoking being significant risk factors. The damage primarily occurs in the macula of the retina, which is essential for central vision. Diagnosis typically involves a comprehensive eye examination, with severity categorized into early, intermediate, and late stages, and with the latter further divided into “dry and wet" forms, with the dry form being more prevalent, constituting about 90% of cases.To know about the Research Methodology :- Request Free Sample Report Age-Related Macular Degeneration (AMD) stands as the primary cause of vision loss and blindness across industrialized nations. Early AMD, also termed dry AMD, is characterized by the presence of drusen and alterations in the retinal pigment epithelium (RPE), typically without noticeable symptoms. This initial RPE abnormality can progress to advanced stages of AMD, resulting in permanent vision loss due to geographic atrophy (GA) and/or choroidal neovascularization (CNV), known as wet AMD. While significant advancements have been achieved in treating wet AMD through intravitreal injections of anti-vascular endothelial growth factor (VEGF) biologics, there remains a pressing need for less invasive treatment options. Furthermore, unlike wet AMD, there are currently no available treatments for dry AMD or GA. The research into three emerging therapeutic target classes of low molecular weight agents for AMD: anti-angiogenesis agents, visual cycle inhibitors, and complement pathway inhibitors, offering promising avenues for the AMD market. For instance, In 2019, an estimated 19.8 million Americans aged 40 and above, representing 12.6% of this demographic, were living with age-related macular degeneration (AMD). Among them, 1.49 million individuals, accounting for 0.94% of the same age group, were living with vision-threatening forms of the condition. The prevalence of AMD increased with advancing age, ranging from 2% among those aged 40 to 44, to as high as 46.6% among individuals aged 85 and above. When considering sex and age adjustments, rates of AMD were found to be lower among non-Hispanic Black individuals, at 7.0% compared to other racial and ethnic groups, with rates estimated at 13.3%. Prevalence of AMD exhibited considerable variation at both the state and county levels, even after accounting for demographic differences. Across states, crude prevalence ranged from a low of 6.2% in the District of Columbia to a high of 18.3% in Florida. Age-related macular degeneration (AMD) impacts roughly 20 million individuals in the United States and 196 million people globally. It stands as a primary cause of significant vision loss among the elderly and is anticipated to affect around 288 million individuals worldwide by the year 2040.
Age Related Macular Degeneration (AMD) Market Dynamics:
Therapeutic Innovations in Age-Related Macular Degeneration (AMD) In the field of age-related macular degeneration (AMD), researchers are exploring various therapeutic approaches to address the complexity of the disease and develop more effective treatments. Some of the key areas of exploration include gene therapy, bioelectronic implants, stem cell therapies, and interventions aimed at reducing the frequency of anti-VEGF injections. These approaches aim to slow down the progression of advanced AMD or even prevent its onset. Clinical trials play a crucial role in evaluating the safety and efficacy of these potential treatments. By examining completed and ongoing clinical trials in the AMD space, researchers can gain valuable insights into the latest developments and advancements in the field. The Age-Related Macular Degeneration (AMD) market is driven by several factors that contribute to its growth and expansion. The aging population worldwide is a significant driver, as AMD primarily affects older individuals, and the prevalence of the condition increases with age. For instance, by 2050, the global population aged 60 years and older is projected to nearly double, creating a larger patient pool for AMD treatments. The advancements in diagnostic technologies play a crucial role in driving market growth. Innovations such as optical coherence tomography (OCT) and genetic testing enable early detection and precise monitoring of AMD progression. This facilitates timely interventions and expands the market by identifying more patients who could benefit from treatment. The emergence of novel therapies offers promising opportunities for market expansion. For example, ongoing research into gene therapy for AMD, such as the clinical trials investigating AAVCAGsCD59, demonstrates the potential of innovative approaches to address unmet medical needs and drive Age Related Macular Degeneration (AMD) Market growth. Additionally, rising healthcare expenditure and increased awareness through education initiatives contribute to Age Related Macular Degeneration (AMD) Market growth. Expanded insurance coverage and access to AMD therapies, coupled with heightened awareness campaigns, encourage proactive management of the condition and drive demand for treatments.Table: Stages of Age-Related Macular Degeneration
Manufacturing and Business Challenges in the Age-Related Macular Degeneration (AMD) Market The complexity of developing and producing advanced therapies, such as gene therapy and stem cell treatments, which require specialized manufacturing processes and stringent quality control measures. For example, the production of gene therapy vectors involves intricate genetic engineering techniques and regulatory compliance to ensure safety and efficacy. Additionally, scalability and cost-effectiveness pose challenges in scaling up production to meet the growing demand for AMD treatments. Business challenges include market competition, intellectual property rights, and regulatory hurdles. Competition among pharmaceutical companies and startups in developing novel AMD therapies intensifies, requiring significant investment in research and development. Protecting intellectual property rights is crucial for companies to safeguard their innovations and maintain a competitive edge. Furthermore, navigating complex regulatory frameworks and obtaining approvals from regulatory agencies such as the FDA and EMA present challenges in bringing AMD therapies to market. Chemical laws vary across regions, impacting production processes and product formulations. For instance, the European Union's REACH regulation restricts the use of certain chemicals in manufacturing, affecting formulation strategies for AMD drugs in the EU market. Similarly, compliance with the FDA's Current Good Manufacturing Practices (cGMP) regulations ensures product quality and safety in the US market, adding complexity to manufacturing operations. Overall, addressing these manufacturing and business challenges while complying with chemical laws is essential for the successful development and commercialization of AMD treatments in various regions. Advancements in Diagnostics, Novel Therapies, and Personalized Medicine Advancements in diagnostic technologies, the emergence of novel therapies, and personalized medicine approaches. Continued innovations in diagnostic tools like optical coherence tomography (OCT) and genetic testing enable earlier detection and precise monitoring of AMD progression, leading to expanded demand for diagnostic devices and services. The ongoing research and development of novel therapies targeting various AMD pathogenesis mechanisms, such as gene therapy and stem cell treatments, offer significant growth prospects by addressing unmet medical needs and driving Age Related Macular Degeneration (AMD) Market growth. Personalized medicine approaches, leveraging genetic testing to identify high-risk individuals for tailored interventions, further enhance treatment efficacy and drive growth in personalized medicine diagnostics and therapies. Strategic partnerships and collaborations between pharmaceutical companies and research institutions accelerate product development timelines and Age Related Macular Degeneration (AMD) Market reach, creating growth opportunities through collaborative efforts. Rising healthcare expenditure, particularly in emerging Age Related Macular Degeneration (AMD) Market, increases accessibility to AMD treatments, while technological innovations in treatment delivery improve efficacy and patient compliance. Moreover, the growing aging population worldwide sustains demand for AMD therapies, while initiatives to improve market access and reimbursement enhance patient access to care. Increase in patient education and awareness campaigns, supported by regulatory frameworks incentivizing innovation, further drive Age Related Macular Degeneration (AMD) Market growth by increasing demand for AMD-related products and services.
Stages Characteristics No AMD - No drusen <br> - No AMD pigmentary abnormalities <br> - Normal dark adaptations Subclinical AMD - No drusen or small drusen <br> - No AMD pigmentary abnormalities <br> - Impaired dark adaptations Early AMD - Small or medium drusen <br> - AMD pigmentary abnormalities <br> - Impaired dark adaptations Intermediate AMD - One large druse <br> - Any AMD pigmentary abnormalities <br> - Impaired dark adaptations Advanced AMD - Geographic atrophy and neovascular AMD Age Related Macular Degeneration (AMD) Market Segment Analysis:
Based on disease type, the market has been divided into Dry AMD and Wet AMD. Among these, the Dry AMD sub-segment is projected to generate the maximum revenue. The Dry AMD sub-segment witnessed the highest market share in the global Age Related Macular Degeneration (AMD) Market in 2023. Dry AMD is more prevalent than Wet AMD, accounting for approximately 85-90% of all AMD cases. This higher prevalence translates to a larger patient population seeking treatment for Dry AMD, driving Age Related Macular Degeneration (AMD) Market demand. Additionally, advancements in diagnostic technologies have improved the early detection and monitoring of Dry AMD, leading to increased awareness and diagnosis rates. Furthermore, there is currently no approved treatment for Dry AMD, resulting in a significant unmet need and driving research and development efforts to develop effective therapies for this sub-type of AMD. In contrast, Wet AMD, while representing a smaller portion of AMD cases, is associated with more severe vision loss and complications. However, the availability of treatment options such as anti-VEGF injections has contributed to better management of Wet AMD compared to Dry AMD. Despite this, the Age Related Macular Degeneration (AMD) Market for Wet AMD is still substantial, driven by the need for ongoing treatment and the continuous development of new therapeutic approaches to improve outcomes for patients with this sub-type of AMD. Additionally, the increasing aging population and rising prevalence of AMD overall contribute to the growth potential of both Dry and Wet AMD markets, with Dry AMD holding a dominant position due to its higher prevalence and unmet treatment needs.Age Related Macular Degeneration (AMD) Market Regional Analysis:
North America region dominated the Age Related Macular Degeneration (AMD) Marketin the year 2023, and is expected to continue its dominance during the forecast period. Several key factors contribute to North America's market dominance, including robust healthcare infrastructure, advanced diagnostic capabilities, strong research and development initiatives, and a large patient population with AMD. One of the primary drivers of North America's dominance in the AMD market is its advanced healthcare infrastructure. The region boasts a well-developed healthcare system with access to state-of-the-art medical facilities, specialized treatment centers, and skilled healthcare professionals. This infrastructure enables timely diagnosis, effective management, and comprehensive care for AMD patients, contributing to the region's leadership in the Age Related Macular Degeneration (AMD) Market. Moreover, North America benefits from advanced diagnostic capabilities, including sophisticated imaging technologies and genetic testing modalities. Techniques such as optical coherence tomography (OCT) and genetic screening allow for early detection, precise monitoring, and personalized treatment approaches for AMD patients. These diagnostic advancements enhance patient outcomes, drive demand for AMD-related services, and reinforce North America's position as a frontrunner in the global market. Additionally, North America's leadership in the AMD market is supported by its strong research and development initiatives. The region is home to numerous pharmaceutical companies, research institutions, and academic centers dedicated to advancing AMD therapeutics. Through collaboration and innovation, these entities drive the development of novel treatments, such as gene therapy, stem cell therapy, and targeted pharmacotherapies, aimed at addressing unmet medical needs in AMD management. The large patient population with AMD in North America contributes to the region's market dominance. Age-related macular degeneration is more prevalent among older individuals, and North America has a significant aging population. With an increasing number of individuals at risk of AMD, there is a growing demand for preventative measures, diagnostic services, and treatment options, driving Age Related Macular Degeneration (AMD) Market growth in the region. In addition to these factors, favorable regulatory frameworks and reimbursement policies further support North America's dominance in the AMD market. Regulatory agencies such as the Food and Drug Administration (FDA) in the United States ensure the safety, efficacy, and timely approval of AMD therapeutics, fostering innovation and Age Related Macular Degeneration (AMD) Market. Reimbursement policies facilitate patient access to AMD treatments, reducing financial barriers and driving demand for AMD-related products and services. North America is poised to maintain its leadership in the global AMD market during the forecast period. The region's advanced healthcare infrastructure, diagnostic capabilities, research and development initiatives, large patient population, and supportive regulatory environment collectively position it as a powerhouse in the field of age-related macular degeneration. As efforts continue to advance AMD therapeutics and improve patient outcomes, North America is expected to remain at the forefront of innovation and market growth in the years to come. Age Related Macular Degeneration (AMD) Market Recent Development: 1. On October 5, 2023, the US FDA has granted clearance for Endogena Therapeutics' investigational new drug application for EA-2351, aimed at treating geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). GA, a chronic-progressive degeneration of the macula, affects an estimated 9% of individuals over 45 years old and can lead to irreversible vision loss. Endogena's EA-2351 targets retinal pigment epithelial (RPE) cells to restore photoreceptor function. This marks Endogena's second clinical investigation, following the ongoing EA-2532 program for retinitis pigmentosa. 2. On December 10, 2023, Belite Bio, Inc. received approval from Swissmedic to initiate the Phase 3 clinical trial of Tinlarebant in Geographic Atrophy (GA), known as the PHOENIX study. Tinlarebant, an orally administered tablet, aims to slow disease progression in patients with Stargardt Disease (STGD1) and advanced Dry Age-related Macular Degeneration (Dry AMD). The trial follows a successful Phase 2 study in STGD1, where Tinlarebant demonstrated safety and sustained lower lesion growth compared to natural history participants. Initiation awaits protocol amendment requested by Swissmedic for Switzerland.The Scope of the Report for Global Age Related Macular Degeneration (AMD) Market: Inquire before buying
Global Age Related Macular Degeneration Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: US $ 10.25 Bn. Forecast Period 2024 to 2030 CAGR: 12.7% Market Size in 2030: US $ 11.25 Bn. Segments Covered: by Drug Type Lucentis Eylea Beovu Others by Disease Type Dry AMD Wet AMD by Age Group Less Than 60 Between 60 to 80 More Than 80 by Gender Male Female Age Related Macular Degeneration Market, By Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Age Related Macular Degeneration (AMD) Market Key Players:
Major Contributors in the Age-Related Macular Degeneration (AMD) Market in North America: 1. Regeneron Pharmaceuticals (United States) 2. Allergan plc. (United States) 3. Genentech (United States) 4. Ophthotech Corporation (United States) 5. Apellis Pharmaceuticals (United States) 6. Graybug Vision (United States) 7. Neurotech Pharmaceuticals, Inc. (United States) 8. IVERIC bio (United States) 9. Adverum Biotechnologies (United States) 10. Tyrogenex (United States) 11. Kodiak Sciences Inc. (United States) 12. Bausch Health Companies Inc. (Canada) Major Leading Player in the Age Related Macular Degeneration (AMD) Market in Europe: 1. Oxurion NV (Belgium) 2. Novartis (Switzerland) 3. Roche (Switzerland) 4. Bayer AG (Germany) Major Leading Player in the Age Related Macular Degeneration (AMD) Market in Asia Pacific: 1. Kubota Vision Inc. (Japan) 2. Opthea Limited (Australia) 3. Chengdu Kanghong Pharmaceutical Group Co., Ltd. (China) 4. Santen Pharmaceutical Co., Ltd. (Japan) FAQ: 1] What segments are covered in the Age Related Macular Degeneration (AMD) Market report? Ans. The segments covered in the Age Related Macular Degeneration (AMD) Market report are based on Drug Type, Disease Type, Age Group, Gender, and Region. 2] Which region is expected to hold the highest share in the Global Age Related Macular Degeneration (AMD) Market? Ans. North America region is expected to hold the highest market share in the Age Related Macular Degeneration (AMD) market. 3] What is the market size of the Global Age Related Macular Degeneration (AMD) Market by 2030? Ans. The market size of the Age-Related Macular Degeneration (AMD) Market by 2030 is expected to reach USD 11.25 Billion. 4] What is the forecast period for the Global Age Related Macular Degeneration (AMD) Market? Ans. The forecast period for the Age-Related Macular Degeneration (AMD) Market is 2024-2030. 5] What was the market size of the Global Age Related Macular Degeneration (AMD) Market in 2023? Ans. The market size of the Age-Related Macular Degeneration (AMD) Market in 2023 was valued at USD 10.52 Billion.
1. Age Related Macular Degeneration Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Age Related Macular Degeneration Market: Dynamics 2.1. Age Related Macular Degeneration Market Trends by Region 2.1.1. North America Age Related Macular Degeneration Market Trends 2.1.2. Europe Age Related Macular Degeneration Market Trends 2.1.3. Asia Pacific Age Related Macular Degeneration Market Trends 2.1.4. Middle East and Africa Age Related Macular Degeneration Market Trends 2.1.5. South America Age Related Macular Degeneration Market Trends 2.2. Age Related Macular Degeneration Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Age Related Macular Degeneration Market Drivers 2.2.1.2. North America Age Related Macular Degeneration Market Restraints 2.2.1.3. North America Age Related Macular Degeneration Market Opportunities 2.2.1.4. North America Age Related Macular Degeneration Market Challenges 2.2.2. Europe 2.2.2.1. Europe Age Related Macular Degeneration Market Drivers 2.2.2.2. Europe Age Related Macular Degeneration Market Restraints 2.2.2.3. Europe Age Related Macular Degeneration Market Opportunities 2.2.2.4. Europe Age Related Macular Degeneration Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Age Related Macular Degeneration Market Drivers 2.2.3.2. Asia Pacific Age Related Macular Degeneration Market Restraints 2.2.3.3. Asia Pacific Age Related Macular Degeneration Market Opportunities 2.2.3.4. Asia Pacific Age Related Macular Degeneration Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Age Related Macular Degeneration Market Drivers 2.2.4.2. Middle East and Africa Age Related Macular Degeneration Market Restraints 2.2.4.3. Middle East and Africa Age Related Macular Degeneration Market Opportunities 2.2.4.4. Middle East and Africa Age Related Macular Degeneration Market Challenges 2.2.5. South America 2.2.5.1. South America Age Related Macular Degeneration Market Drivers 2.2.5.2. South America Age Related Macular Degeneration Market Restraints 2.2.5.3. South America Age Related Macular Degeneration Market Opportunities 2.2.5.4. South America Age Related Macular Degeneration Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Age Related Macular Degeneration Industry 2.8. Analysis of Government Schemes and Initiatives For Age Related Macular Degeneration Industry 2.9. Age Related Macular Degeneration Market Trade Analysis 2.10. The Global Pandemic Impact on Age Related Macular Degeneration Market 3. Age Related Macular Degeneration Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2023-2030 3.1. Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 3.1.1. Lucentis 3.1.2. Eylea 3.1.3. Beovu 3.1.4. Others 3.2. Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 3.2.1. Dry AMD 3.2.2. Wet AMD 3.3. Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 3.3.1. Less Than 60 3.3.2. Between 60 to 80 3.3.3. More Than 80 3.4. Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 3.4.1. Male 3.4.2. Female 3.5. Age Related Macular Degeneration Market Size and Forecast, by Region (2023-2030) 3.5.1. North America 3.5.2. Europe 3.5.3. Asia Pacific 3.5.4. Middle East and Africa 3.5.5. South America 4. North America Age Related Macular Degeneration Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 4.1. North America Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 4.1.1. Lucentis 4.1.2. Eylea 4.1.3. Beovu 4.1.4. Others 4.2. North America Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 4.2.1. Dry AMD 4.2.2. Wet AMD 4.3. North America Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 4.3.1. Less Than 60 4.3.2. Between 60 to 80 4.3.3. More Than 80 4.4. North America Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 4.4.1. Male 4.4.2. Female 4.5. North America Age Related Macular Degeneration Market Size and Forecast, by Country (2023-2030) 4.5.1. United States 4.5.1.1. United States Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 4.5.1.1.1. Lucentis 4.5.1.1.2. Eylea 4.5.1.1.3. Beovu 4.5.1.1.4. Others 4.5.1.2. United States Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 4.5.1.2.1. Dry AMD 4.5.1.2.2. Wet AMD 4.5.1.3. United States Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 4.5.1.3.1. Less Than 60 4.5.1.3.2. Between 60 to 80 4.5.1.3.3. More Than 80 4.5.1.4. United States Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 4.5.1.4.1. Male 4.5.1.4.2. Female 4.5.2. Canada 4.5.2.1. Canada Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 4.5.2.1.1. Lucentis 4.5.2.1.2. Eylea 4.5.2.1.3. Beovu 4.5.2.1.4. Others 4.5.2.2. Canada Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 4.5.2.2.1. Dry AMD 4.5.2.2.2. Wet AMD 4.5.2.3. Canada Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 4.5.2.3.1. Less Than 60 4.5.2.3.2. Between 60 to 80 4.5.2.3.3. More Than 80 4.5.2.4. Canada Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 4.5.2.4.1. Male 4.5.2.4.2. Female 4.5.3. Mexico 4.5.3.1. Mexico Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 4.5.3.1.1. Lucentis 4.5.3.1.2. Eylea 4.5.3.1.3. Beovu 4.5.3.1.4. Others 4.5.3.2. Mexico Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 4.5.3.2.1. Dry AMD 4.5.3.2.2. Wet AMD 4.5.3.3. Mexico Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 4.5.3.3.1. Less Than 60 4.5.3.3.2. Between 60 to 80 4.5.3.3.3. More Than 80 4.5.3.4. Mexico Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 4.5.3.4.1. Male 4.5.3.4.2. Female 5. Europe Age Related Macular Degeneration Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 5.1. Europe Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 5.2. Europe Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 5.3. Europe Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 5.4. Europe Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 5.5. Europe Age Related Macular Degeneration Market Size and Forecast, by Country (2023-2030) 5.5.1. United Kingdom 5.5.1.1. United Kingdom Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 5.5.1.2. United Kingdom Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 5.5.1.3. United Kingdom Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 5.5.1.4. United Kingdom Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 5.5.2. France 5.5.2.1. France Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 5.5.2.2. France Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 5.5.2.3. France Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 5.5.2.4. France Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 5.5.3. Germany 5.5.3.1. Germany Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 5.5.3.2. Germany Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 5.5.3.3. Germany Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 5.5.3.4. Germany Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 5.5.4. Italy 5.5.4.1. Italy Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 5.5.4.2. Italy Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 5.5.4.3. Italy Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 5.5.4.4. Italy Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 5.5.5. Spain 5.5.5.1. Spain Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 5.5.5.2. Spain Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 5.5.5.3. Spain Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 5.5.5.4. Spain Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 5.5.6. Sweden 5.5.6.1. Sweden Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 5.5.6.2. Sweden Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 5.5.6.3. Sweden Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 5.5.6.4. Sweden Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 5.5.7. Austria 5.5.7.1. Austria Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 5.5.7.2. Austria Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 5.5.7.3. Austria Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 5.5.7.4. Austria Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 5.5.8. Rest of Europe 5.5.8.1. Rest of Europe Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 5.5.8.2. Rest of Europe Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 5.5.8.3. Rest of Europe Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 5.5.8.4. Rest of Europe Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 6. Asia Pacific Age Related Macular Degeneration Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 6.1. Asia Pacific Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 6.2. Asia Pacific Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 6.3. Asia Pacific Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 6.4. Asia Pacific Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 6.5. Asia Pacific Age Related Macular Degeneration Market Size and Forecast, by Country (2023-2030) 6.5.1. China 6.5.1.1. China Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 6.5.1.2. China Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 6.5.1.3. China Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 6.5.1.4. China Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 6.5.2. S Korea 6.5.2.1. S Korea Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 6.5.2.2. S Korea Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 6.5.2.3. S Korea Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 6.5.2.4. S Korea Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 6.5.3. Japan 6.5.3.1. Japan Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 6.5.3.2. Japan Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 6.5.3.3. Japan Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 6.5.3.4. Japan Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 6.5.4. India 6.5.4.1. India Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 6.5.4.2. India Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 6.5.4.3. India Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 6.5.4.4. India Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 6.5.5. Australia 6.5.5.1. Australia Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 6.5.5.2. Australia Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 6.5.5.3. Australia Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 6.5.5.4. Australia Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 6.5.6. Indonesia 6.5.6.1. Indonesia Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 6.5.6.2. Indonesia Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 6.5.6.3. Indonesia Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 6.5.6.4. Indonesia Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 6.5.7. Malaysia 6.5.7.1. Malaysia Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 6.5.7.2. Malaysia Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 6.5.7.3. Malaysia Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 6.5.7.4. Malaysia Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 6.5.8. Vietnam 6.5.8.1. Vietnam Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 6.5.8.2. Vietnam Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 6.5.8.3. Vietnam Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 6.5.8.4. Vietnam Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 6.5.9. Taiwan 6.5.9.1. Taiwan Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 6.5.9.2. Taiwan Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 6.5.9.3. Taiwan Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 6.5.9.4. Taiwan Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 6.5.10. Rest of Asia Pacific 6.5.10.1. Rest of Asia Pacific Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 6.5.10.2. Rest of Asia Pacific Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 6.5.10.3. Rest of Asia Pacific Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 6.5.10.4. Rest of Asia Pacific Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 7. Middle East and Africa Age Related Macular Degeneration Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 7.1. Middle East and Africa Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 7.2. Middle East and Africa Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 7.3. Middle East and Africa Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 7.4. Middle East and Africa Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 7.5. Middle East and Africa Age Related Macular Degeneration Market Size and Forecast, by Country (2023-2030) 7.5.1. South Africa 7.5.1.1. South Africa Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 7.5.1.2. South Africa Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 7.5.1.3. South Africa Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 7.5.1.4. South Africa Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 7.5.2. GCC 7.5.2.1. GCC Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 7.5.2.2. GCC Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 7.5.2.3. GCC Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 7.5.2.4. GCC Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 7.5.3. Nigeria 7.5.3.1. Nigeria Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 7.5.3.2. Nigeria Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 7.5.3.3. Nigeria Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 7.5.3.4. Nigeria Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 7.5.4. Rest of ME&A 7.5.4.1. Rest of ME&A Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 7.5.4.2. Rest of ME&A Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 7.5.4.3. Rest of ME&A Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 7.5.4.4. Rest of ME&A Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 8. South America Age Related Macular Degeneration Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 8.1. South America Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 8.2. South America Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 8.3. South America Age Related Macular Degeneration Market Size and Forecast, by Age Group(2023-2030) 8.4. South America Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 8.5. South America Age Related Macular Degeneration Market Size and Forecast, by Country (2023-2030) 8.5.1. Brazil 8.5.1.1. Brazil Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 8.5.1.2. Brazil Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 8.5.1.3. Brazil Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 8.5.1.4. Brazil Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 8.5.2. Argentina 8.5.2.1. Argentina Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 8.5.2.2. Argentina Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 8.5.2.3. Argentina Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 8.5.2.4. Argentina Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 8.5.3. Rest Of South America 8.5.3.1. Rest Of South America Age Related Macular Degeneration Market Size and Forecast, by Drug Type (2023-2030) 8.5.3.2. Rest Of South America Age Related Macular Degeneration Market Size and Forecast, by Disease Type (2023-2030) 8.5.3.3. Rest Of South America Age Related Macular Degeneration Market Size and Forecast, by Age Group (2023-2030) 8.5.3.4. Rest Of South America Age Related Macular Degeneration Market Size and Forecast, by Gender (2023-2030) 9. Global Age Related Macular Degeneration Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Age Related Macular Degeneration Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Regeneron Pharmaceuticals (United States) 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Allergan (United States) 10.3. Genentech (United States) 10.4. Ophthotech Corporation (United States) 10.5. Apellis Pharmaceuticals (United States) 10.6. Graybug Vision (United States) 10.7. Neurotech Pharmaceuticals, Inc. (United States) 10.8. IVERIC bio (United States) 10.9. Adverum Biotechnologies (United States) 10.10. Tyrogenex (United States) 10.11. Kodiak Sciences Inc. (United States) 10.12. Bausch Health Companies Inc. (Canada) 10.13. Oxurion NV (Belgium) 10.14. Novartis (Switzerland) 10.15. Roche (Switzerland) 10.16. Bayer AG (Germany) 10.17. Kubota Vision Inc. (Japan) 10.18. Opthea Limited (Australia) 10.19. Chengdu Kanghong Pharmaceutical Group Co., Ltd. (China) 10.20. Santen Pharmaceutical Co., Ltd. (Japan) 11. Key Findings 12. Industry Recommendations 13. Age Related Macular Degeneration Market: Research Methodology 14. Terms and Glossary
